Opioid Use Disorder

Global Opioid Use Disorder Market to Reach US$10.6 Billion by 2030

The global market for Opioid Use Disorder estimated at US$5.7 Billion in the year 2024, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 10.9% over the analysis period 2024-2030. Buprenorphine Drug, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Naltrexone Drug segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 9.8% CAGR

The Opioid Use Disorder market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Opioid Use Disorder Market – Key Trends & Drivers Summarized

Why Is Opioid Use Disorder a Persistent Global Health Crisis Demanding Scalable Interventions?

Opioid Use Disorder (OUD) has escalated into a major public health emergency worldwide, particularly in North America, where synthetic opioids such as fentanyl have driven unprecedented overdose rates. The chronic, relapsing nature of OUD and its widespread socio-economic consequences have led to urgent calls for comprehensive treatment infrastructure and long-term care solutions. While awareness of the epidemic has grown significantly, so has the complexity of the crisis, which involves not only illicit drug use but also the over-prescription of opioids for pain management. With millions affected globally, healthcare systems are under pressure to adopt integrated, multi-modal approaches combining medication-assisted treatment (MAT), behavioral therapy, harm reduction, and social support. The stigma surrounding addiction, gaps in healthcare access, and the criminalization of substance use continue to hinder effective intervention strategies. However, increased public health funding, greater availability of treatment centers, and shifting perceptions of addiction as a treatable medical condition are fostering a more supportive environment for recovery. In this context, the market for OUD treatments is expanding as governments, healthcare providers, and private sector players prioritize scalable, evidence-based solutions that address both the physiological and psychological aspects of opioid dependency.

How Are Advancements in Treatment Modalities Shaping Recovery Outcomes?

The therapeutic landscape for Opioid Use Disorder is rapidly evolving, with innovation focused on improving the efficacy, safety, and accessibility of treatment options. Medication-assisted treatments (MATs) remain the cornerstone of OUD management, with methadone, buprenorphine, and naltrexone being widely used to reduce cravings, block opioid effects, and support recovery. Recent years have seen the development of extended-release formulations and implantable devices that ensure sustained medication delivery, reduce dosing frequency, and improve adherence—critical factors in long-term recovery. Novel combination therapies are also emerging to address both opioid dependence and co-occurring conditions such as depression or anxiety. Digital therapeutics and telehealth-based counseling platforms are gaining ground, especially post-COVID-19, enabling remote monitoring, therapy access, and adherence tracking. Wearable biosensors and mobile apps that provide real-time feedback and relapse alerts are being explored to support patients outside clinical environments. Additionally, research into vaccines and antagonists that block opioid receptors before the drug can exert its effects is progressing, holding promise for future prevention strategies. These advancements are not only improving patient outcomes but are also expanding treatment options in underserved and rural areas, where traditional infrastructure may be lacking.

What Systemic and Regional Factors Are Influencing Market Demand and Accessibility?

The demand for Opioid Use Disorder treatment solutions varies significantly across regions due to differences in healthcare infrastructure, policy frameworks, and socio-cultural attitudes toward addiction. In the United States and Canada, where the opioid crisis has reached epidemic levels, the focus is on expanding access to MAT, harm reduction services like naloxone distribution and safe injection sites, and integrating OUD treatment into primary care and emergency services. These countries have also seen strong government funding and regulatory support for new treatment products, including fast-tracked approvals and reimbursement programs. In contrast, developing nations often face limited access to both opioids for pain management and OUD therapies due to restrictive drug policies and underfunded healthcare systems. Stigma remains a barrier worldwide, often deterring individuals from seeking treatment or governments from investing in addiction care. However, global initiatives by organizations such as the WHO and UNODC are driving awareness and capacity-building efforts, particularly in Eastern Europe, Latin America, and parts of Asia. Meanwhile, criminal justice reforms in several countries are redirecting drug users toward treatment instead of incarceration, thereby expanding institutional demand for OUD solutions. These regional disparities and policy shifts are playing a pivotal role in shaping where and how the market for OUD treatment products and services is developing.

What Are the Primary Forces Driving Growth in the Opioid Use Disorder Market?

The growth in the Opioid Use Disorder market is driven by several factors related to rising disease prevalence, evolving treatment paradigms, technology integration, and policy shifts. A critical driver is the increasing global incidence of opioid addiction and related deaths, which is prompting urgent healthcare interventions and sustained public health funding. The widespread acceptance of medication-assisted treatment as the gold standard for OUD care is driving demand for methadone, buprenorphine, and naltrexone products, especially long-acting injectable formulations that improve adherence. Expansion of telehealth services is making treatment more accessible, particularly in rural and underserved communities, while digital platforms are facilitating patient engagement, therapy scheduling, and medication management. Regulatory support, including fast-track drug approvals, expanded prescribing authority for non-specialist providers, and insurance reimbursement reforms, is accelerating market penetration. Pharmaceutical innovation is also playing a key role, with companies investing in abuse-deterrent formulations, implants, and novel delivery methods to improve patient outcomes. Additionally, the decriminalization of substance use and the growing use of OUD treatment in correctional health systems are generating new institutional demand. Public-private partnerships and global awareness campaigns are further mobilizing resources and expanding the availability of OUD treatment across various healthcare settings. Collectively, these forces are fostering a robust, multi-faceted market environment focused on long-term recovery and systemic resilience.

SCOPE OF STUDY:

The report analyzes the Opioid Use Disorder market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug (Buprenorphine Drug, Naltrexone Drug, Methadone Drug, Other Drugs); Route of Administration (Injectable Route of Administration, Oral Route of Administration, Other Route of Administrations); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• Acadia Healthcare
• Alkermes plc
• Amneal Pharmaceuticals, Inc.
• BioDelivery Sciences International Inc.
• Camurus AB
• Collegium Pharmaceutical
• Hikma Pharmaceuticals PLC
• Indivior PLC
• Johnson & Johnson
• Lannett Company, Inc.
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Omeros Corporation
• Opiant Pharmaceuticals, Inc.
• Orexo AB
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Titan Pharmaceuticals, Inc.
• Viatris Inc. (Mylan N.V.)
• West Pharmaceutical Services, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.